Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss

Company Overview - Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel psychedelic-derived therapeutics to address significant health issues, including alcohol use disorder [4][5] - The company has filed multiple patent applications in collaboration with SciSparc Ltd. for various proprietary compositions aimed at treating alcohol use disorder, cocaine addiction, obesity, and related metabolic disorders [3][5] Market Insights - The global obesity treatment market was valued at $15 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 10.0% from 2023 to 2032, driven by the rising prevalence of obesity and advancements in weight loss technologies [2] Intellectual Property - Clearmind's intellectual property portfolio includes eighteen patent families with 28 granted patents, and the company plans to pursue additional patents as opportunities arise [7] - A recent patent application pertains to a novel composition combining Clearmind's MEAI compound with Palmitoylethanolamide (PEA) for treating metabolic syndrome and obesity [6]